

Global COVID-19 Inactivated Vaccine Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/G7AEB83095E7EN.html>

Date: August 2024

Pages: 154

Price: US\$ 3,200.00 (Single User License)

ID: G7AEB83095E7EN

Abstracts

Report Overview

This report provides a deep insight into the global COVID-19 Inactivated Vaccine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global COVID-19 Inactivated Vaccine Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the COVID-19 Inactivated Vaccine market in any manner.

Global COVID-19 Inactivated Vaccine Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding

the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Inovio Pharmaceuticals

Takis Biotech (Evvivax)

Zydus Cadila

Codagenix, Inc.

GeoVax, Inc.

Bravovax

Janssen Pharmaceutical Companies

Altimune

Vaxart

CanSino Biologics

ExpreS2ion Biotechnologies ApS

Clover Biopharmaceuticals

GSK

Vaxil Bio Ltd.

Generex

Novavax, Inc.

Sanofi Pasteur

Baylor

iBio, Inc.

Moderna, Inc.

Curevac

ImmunoPrecise

Market Segmentation (by Type)

In Clinical Trials

Out-of-Clinical Trials

Market Segmentation (by Application)

Hospital

Clinic

Other

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the COVID-19 Inactivated Vaccine Market

Overview of the regional outlook of the COVID-19 Inactivated Vaccine Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth

as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product

type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the COVID-19 Inactivated Vaccine Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of COVID-19 Inactivated Vaccine

1.2 Key Market Segments

1.2.1 COVID-19 Inactivated Vaccine Segment by Type

1.2.2 COVID-19 Inactivated Vaccine Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 COVID-19 INACTIVATED VACCINE MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global COVID-19 Inactivated Vaccine Market Size (M USD) Estimates and Forecasts (2019-2030)

2.1.2 Global COVID-19 Inactivated Vaccine Sales Estimates and Forecasts (2019-2030)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 COVID-19 INACTIVATED VACCINE MARKET COMPETITIVE LANDSCAPE

3.1 Global COVID-19 Inactivated Vaccine Sales by Manufacturers (2019-2024)

3.2 Global COVID-19 Inactivated Vaccine Revenue Market Share by Manufacturers (2019-2024)

3.3 COVID-19 Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global COVID-19 Inactivated Vaccine Average Price by Manufacturers (2019-2024)

3.5 Manufacturers COVID-19 Inactivated Vaccine Sales Sites, Area Served, Product Type

3.6 COVID-19 Inactivated Vaccine Market Competitive Situation and Trends

3.6.1 COVID-19 Inactivated Vaccine Market Concentration Rate

3.6.2 Global 5 and 10 Largest COVID-19 Inactivated Vaccine Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 COVID-19 INACTIVATED VACCINE INDUSTRY CHAIN ANALYSIS

4.1 COVID-19 Inactivated Vaccine Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF COVID-19 INACTIVATED VACCINE MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

6 COVID-19 INACTIVATED VACCINE MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global COVID-19 Inactivated Vaccine Sales Market Share by Type (2019-2024)

6.3 Global COVID-19 Inactivated Vaccine Market Size Market Share by Type (2019-2024)

6.4 Global COVID-19 Inactivated Vaccine Price by Type (2019-2024)

7 COVID-19 INACTIVATED VACCINE MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global COVID-19 Inactivated Vaccine Market Sales by Application (2019-2024)

7.3 Global COVID-19 Inactivated Vaccine Market Size (M USD) by Application (2019-2024)

7.4 Global COVID-19 Inactivated Vaccine Sales Growth Rate by Application (2019-2024)

8 COVID-19 INACTIVATED VACCINE MARKET SEGMENTATION BY REGION

8.1 Global COVID-19 Inactivated Vaccine Sales by Region

8.1.1 Global COVID-19 Inactivated Vaccine Sales by Region

8.1.2 Global COVID-19 Inactivated Vaccine Sales Market Share by Region

8.2 North America

8.2.1 North America COVID-19 Inactivated Vaccine Sales by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe COVID-19 Inactivated Vaccine Sales by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

8.4 Asia Pacific

8.4.1 Asia Pacific COVID-19 Inactivated Vaccine Sales by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

8.5 South America

8.5.1 South America COVID-19 Inactivated Vaccine Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa COVID-19 Inactivated Vaccine Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 KEY COMPANIES PROFILE

9.1 Inovio Pharmaceuticals

- 9.1.1 Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Basic Information
- 9.1.2 Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Product Overview
- 9.1.3 Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Product Market Performance
- 9.1.4 Inovio Pharmaceuticals Business Overview
- 9.1.5 Inovio Pharmaceuticals COVID-19 Inactivated Vaccine SWOT Analysis
- 9.1.6 Inovio Pharmaceuticals Recent Developments

9.2 Takis Biotech (Evvivax)

- 9.2.1 Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Basic Information
- 9.2.2 Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Product Overview
- 9.2.3 Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Product Market Performance
- 9.2.4 Takis Biotech (Evvivax) Business Overview
- 9.2.5 Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine SWOT Analysis
- 9.2.6 Takis Biotech (Evvivax) Recent Developments

9.3 Zydus Cadila

- 9.3.1 Zydus Cadila COVID-19 Inactivated Vaccine Basic Information
- 9.3.2 Zydus Cadila COVID-19 Inactivated Vaccine Product Overview
- 9.3.3 Zydus Cadila COVID-19 Inactivated Vaccine Product Market Performance
- 9.3.4 Zydus Cadila COVID-19 Inactivated Vaccine SWOT Analysis
- 9.3.5 Zydus Cadila Business Overview
- 9.3.6 Zydus Cadila Recent Developments

9.4 Codagenix, Inc.

- 9.4.1 Codagenix, Inc. COVID-19 Inactivated Vaccine Basic Information
- 9.4.2 Codagenix, Inc. COVID-19 Inactivated Vaccine Product Overview
- 9.4.3 Codagenix, Inc. COVID-19 Inactivated Vaccine Product Market Performance
- 9.4.4 Codagenix, Inc. Business Overview
- 9.4.5 Codagenix, Inc. Recent Developments

9.5 GeoVax, Inc.

- 9.5.1 GeoVax, Inc. COVID-19 Inactivated Vaccine Basic Information
- 9.5.2 GeoVax, Inc. COVID-19 Inactivated Vaccine Product Overview
- 9.5.3 GeoVax, Inc. COVID-19 Inactivated Vaccine Product Market Performance
- 9.5.4 GeoVax, Inc. Business Overview
- 9.5.5 GeoVax, Inc. Recent Developments

9.6 Bravovax

- 9.6.1 Bravovax COVID-19 Inactivated Vaccine Basic Information
- 9.6.2 Bravovax COVID-19 Inactivated Vaccine Product Overview

- 9.6.3 Bravovax COVID-19 Inactivated Vaccine Product Market Performance
- 9.6.4 Bravovax Business Overview
- 9.6.5 Bravovax Recent Developments
- 9.7 Janssen Pharmaceutical Companies
 - 9.7.1 Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Basic Information
 - 9.7.2 Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Product Overview
 - 9.7.3 Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Product Market Performance
 - 9.7.4 Janssen Pharmaceutical Companies Business Overview
 - 9.7.5 Janssen Pharmaceutical Companies Recent Developments
- 9.8 Altimune
 - 9.8.1 Altimune COVID-19 Inactivated Vaccine Basic Information
 - 9.8.2 Altimune COVID-19 Inactivated Vaccine Product Overview
 - 9.8.3 Altimune COVID-19 Inactivated Vaccine Product Market Performance
 - 9.8.4 Altimune Business Overview
 - 9.8.5 Altimune Recent Developments
- 9.9 Vaxart
 - 9.9.1 Vaxart COVID-19 Inactivated Vaccine Basic Information
 - 9.9.2 Vaxart COVID-19 Inactivated Vaccine Product Overview
 - 9.9.3 Vaxart COVID-19 Inactivated Vaccine Product Market Performance
 - 9.9.4 Vaxart Business Overview
 - 9.9.5 Vaxart Recent Developments
- 9.10 CanSino Biologics
 - 9.10.1 CanSino Biologics COVID-19 Inactivated Vaccine Basic Information
 - 9.10.2 CanSino Biologics COVID-19 Inactivated Vaccine Product Overview
 - 9.10.3 CanSino Biologics COVID-19 Inactivated Vaccine Product Market Performance
 - 9.10.4 CanSino Biologics Business Overview
 - 9.10.5 CanSino Biologics Recent Developments
- 9.11 ExpreS2ion Biotechnologies ApS
 - 9.11.1 ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Basic Information
 - 9.11.2 ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Product Overview
 - 9.11.3 ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Product Market Performance
 - 9.11.4 ExpreS2ion Biotechnologies ApS Business Overview
 - 9.11.5 ExpreS2ion Biotechnologies ApS Recent Developments

9.12 Clover Biopharmaceuticals

9.12.1 Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Basic Information

9.12.2 Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Product Overview

9.12.3 Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Product Market

Performance

9.12.4 Clover Biopharmaceuticals Business Overview

9.12.5 Clover Biopharmaceuticals Recent Developments

9.13 GSK

9.13.1 GSK COVID-19 Inactivated Vaccine Basic Information

9.13.2 GSK COVID-19 Inactivated Vaccine Product Overview

9.13.3 GSK COVID-19 Inactivated Vaccine Product Market Performance

9.13.4 GSK Business Overview

9.13.5 GSK Recent Developments

9.14 Vaxil Bio Ltd.

9.14.1 Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Basic Information

9.14.2 Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Product Overview

9.14.3 Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Product Market Performance

9.14.4 Vaxil Bio Ltd. Business Overview

9.14.5 Vaxil Bio Ltd. Recent Developments

9.15 Generex

9.15.1 Generex COVID-19 Inactivated Vaccine Basic Information

9.15.2 Generex COVID-19 Inactivated Vaccine Product Overview

9.15.3 Generex COVID-19 Inactivated Vaccine Product Market Performance

9.15.4 Generex Business Overview

9.15.5 Generex Recent Developments

9.16 Novavax, Inc.

9.16.1 Novavax, Inc. COVID-19 Inactivated Vaccine Basic Information

9.16.2 Novavax, Inc. COVID-19 Inactivated Vaccine Product Overview

9.16.3 Novavax, Inc. COVID-19 Inactivated Vaccine Product Market Performance

9.16.4 Novavax, Inc. Business Overview

9.16.5 Novavax, Inc. Recent Developments

9.17 Sanofi Pasteur

9.17.1 Sanofi Pasteur COVID-19 Inactivated Vaccine Basic Information

9.17.2 Sanofi Pasteur COVID-19 Inactivated Vaccine Product Overview

9.17.3 Sanofi Pasteur COVID-19 Inactivated Vaccine Product Market Performance

9.17.4 Sanofi Pasteur Business Overview

9.17.5 Sanofi Pasteur Recent Developments

9.18 Baylor

9.18.1 Baylor COVID-19 Inactivated Vaccine Basic Information

- 9.18.2 Baylor COVID-19 Inactivated Vaccine Product Overview
- 9.18.3 Baylor COVID-19 Inactivated Vaccine Product Market Performance
- 9.18.4 Baylor Business Overview
- 9.18.5 Baylor Recent Developments
- 9.19 iBio, Inc.
 - 9.19.1 iBio, Inc. COVID-19 Inactivated Vaccine Basic Information
 - 9.19.2 iBio, Inc. COVID-19 Inactivated Vaccine Product Overview
 - 9.19.3 iBio, Inc. COVID-19 Inactivated Vaccine Product Market Performance
 - 9.19.4 iBio, Inc. Business Overview
 - 9.19.5 iBio, Inc. Recent Developments
- 9.20 Moderna, Inc.
 - 9.20.1 Moderna, Inc. COVID-19 Inactivated Vaccine Basic Information
 - 9.20.2 Moderna, Inc. COVID-19 Inactivated Vaccine Product Overview
 - 9.20.3 Moderna, Inc. COVID-19 Inactivated Vaccine Product Market Performance
 - 9.20.4 Moderna, Inc. Business Overview
 - 9.20.5 Moderna, Inc. Recent Developments
- 9.21 Curevac
 - 9.21.1 Curevac COVID-19 Inactivated Vaccine Basic Information
 - 9.21.2 Curevac COVID-19 Inactivated Vaccine Product Overview
 - 9.21.3 Curevac COVID-19 Inactivated Vaccine Product Market Performance
 - 9.21.4 Curevac Business Overview
 - 9.21.5 Curevac Recent Developments
- 9.22 ImmunoPrecise
 - 9.22.1 ImmunoPrecise COVID-19 Inactivated Vaccine Basic Information
 - 9.22.2 ImmunoPrecise COVID-19 Inactivated Vaccine Product Overview
 - 9.22.3 ImmunoPrecise COVID-19 Inactivated Vaccine Product Market Performance
 - 9.22.4 ImmunoPrecise Business Overview
 - 9.22.5 ImmunoPrecise Recent Developments

10 COVID-19 INACTIVATED VACCINE MARKET FORECAST BY REGION

- 10.1 Global COVID-19 Inactivated Vaccine Market Size Forecast
- 10.2 Global COVID-19 Inactivated Vaccine Market Forecast by Region
 - 10.2.1 North America Market Size Forecast by Country
 - 10.2.2 Europe COVID-19 Inactivated Vaccine Market Size Forecast by Country
 - 10.2.3 Asia Pacific COVID-19 Inactivated Vaccine Market Size Forecast by Region
 - 10.2.4 South America COVID-19 Inactivated Vaccine Market Size Forecast by Country
 - 10.2.5 Middle East and Africa Forecasted Consumption of COVID-19 Inactivated Vaccine by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)

11.1 Global COVID-19 Inactivated Vaccine Market Forecast by Type (2025-2030)

11.1.1 Global Forecasted Sales of COVID-19 Inactivated Vaccine by Type (2025-2030)

11.1.2 Global COVID-19 Inactivated Vaccine Market Size Forecast by Type (2025-2030)

11.1.3 Global Forecasted Price of COVID-19 Inactivated Vaccine by Type (2025-2030)

11.2 Global COVID-19 Inactivated Vaccine Market Forecast by Application (2025-2030)

11.2.1 Global COVID-19 Inactivated Vaccine Sales (K Units) Forecast by Application

11.2.2 Global COVID-19 Inactivated Vaccine Market Size (M USD) Forecast by Application (2025-2030)

12 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

- Table 1. Introduction of the Type
- Table 2. Introduction of the Application
- Table 3. Market Size (M USD) Segment Executive Summary
- Table 4. COVID-19 Inactivated Vaccine Market Size Comparison by Region (M USD)
- Table 5. Global COVID-19 Inactivated Vaccine Sales (K Units) by Manufacturers (2019-2024)
- Table 6. Global COVID-19 Inactivated Vaccine Sales Market Share by Manufacturers (2019-2024)
- Table 7. Global COVID-19 Inactivated Vaccine Revenue (M USD) by Manufacturers (2019-2024)
- Table 8. Global COVID-19 Inactivated Vaccine Revenue Share by Manufacturers (2019-2024)
- Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Inactivated Vaccine as of 2022)
- Table 10. Global Market COVID-19 Inactivated Vaccine Average Price (USD/Unit) of Key Manufacturers (2019-2024)
- Table 11. Manufacturers COVID-19 Inactivated Vaccine Sales Sites and Area Served
- Table 12. Manufacturers COVID-19 Inactivated Vaccine Product Type
- Table 13. Global COVID-19 Inactivated Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 14. Mergers & Acquisitions, Expansion Plans
- Table 15. Industry Chain Map of COVID-19 Inactivated Vaccine
- Table 16. Market Overview of Key Raw Materials
- Table 17. Midstream Market Analysis
- Table 18. Downstream Customer Analysis
- Table 19. Key Development Trends
- Table 20. Driving Factors
- Table 21. COVID-19 Inactivated Vaccine Market Challenges
- Table 22. Global COVID-19 Inactivated Vaccine Sales by Type (K Units)
- Table 23. Global COVID-19 Inactivated Vaccine Market Size by Type (M USD)
- Table 24. Global COVID-19 Inactivated Vaccine Sales (K Units) by Type (2019-2024)
- Table 25. Global COVID-19 Inactivated Vaccine Sales Market Share by Type (2019-2024)
- Table 26. Global COVID-19 Inactivated Vaccine Market Size (M USD) by Type (2019-2024)

- Table 27. Global COVID-19 Inactivated Vaccine Market Size Share by Type (2019-2024)
- Table 28. Global COVID-19 Inactivated Vaccine Price (USD/Unit) by Type (2019-2024)
- Table 29. Global COVID-19 Inactivated Vaccine Sales (K Units) by Application
- Table 30. Global COVID-19 Inactivated Vaccine Market Size by Application
- Table 31. Global COVID-19 Inactivated Vaccine Sales by Application (2019-2024) & (K Units)
- Table 32. Global COVID-19 Inactivated Vaccine Sales Market Share by Application (2019-2024)
- Table 33. Global COVID-19 Inactivated Vaccine Sales by Application (2019-2024) & (M USD)
- Table 34. Global COVID-19 Inactivated Vaccine Market Share by Application (2019-2024)
- Table 35. Global COVID-19 Inactivated Vaccine Sales Growth Rate by Application (2019-2024)
- Table 36. Global COVID-19 Inactivated Vaccine Sales by Region (2019-2024) & (K Units)
- Table 37. Global COVID-19 Inactivated Vaccine Sales Market Share by Region (2019-2024)
- Table 38. North America COVID-19 Inactivated Vaccine Sales by Country (2019-2024) & (K Units)
- Table 39. Europe COVID-19 Inactivated Vaccine Sales by Country (2019-2024) & (K Units)
- Table 40. Asia Pacific COVID-19 Inactivated Vaccine Sales by Region (2019-2024) & (K Units)
- Table 41. South America COVID-19 Inactivated Vaccine Sales by Country (2019-2024) & (K Units)
- Table 42. Middle East and Africa COVID-19 Inactivated Vaccine Sales by Region (2019-2024) & (K Units)
- Table 43. Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Basic Information
- Table 44. Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Product Overview
- Table 45. Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 46. Inovio Pharmaceuticals Business Overview
- Table 47. Inovio Pharmaceuticals COVID-19 Inactivated Vaccine SWOT Analysis
- Table 48. Inovio Pharmaceuticals Recent Developments
- Table 49. Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Basic Information
- Table 50. Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Product Overview
- Table 51. Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Sales (K Units),

Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 52. Takis Biotech (Evvivax) Business Overview

Table 53. Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine SWOT Analysis

Table 54. Takis Biotech (Evvivax) Recent Developments

Table 55. Zydus Cadila COVID-19 Inactivated Vaccine Basic Information

Table 56. Zydus Cadila COVID-19 Inactivated Vaccine Product Overview

Table 57. Zydus Cadila COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 58. Zydus Cadila COVID-19 Inactivated Vaccine SWOT Analysis

Table 59. Zydus Cadila Business Overview

Table 60. Zydus Cadila Recent Developments

Table 61. Codagenix, Inc. COVID-19 Inactivated Vaccine Basic Information

Table 62. Codagenix, Inc. COVID-19 Inactivated Vaccine Product Overview

Table 63. Codagenix, Inc. COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 64. Codagenix, Inc. Business Overview

Table 65. Codagenix, Inc. Recent Developments

Table 66. GeoVax, Inc. COVID-19 Inactivated Vaccine Basic Information

Table 67. GeoVax, Inc. COVID-19 Inactivated Vaccine Product Overview

Table 68. GeoVax, Inc. COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 69. GeoVax, Inc. Business Overview

Table 70. GeoVax, Inc. Recent Developments

Table 71. Bravovax COVID-19 Inactivated Vaccine Basic Information

Table 72. Bravovax COVID-19 Inactivated Vaccine Product Overview

Table 73. Bravovax COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 74. Bravovax Business Overview

Table 75. Bravovax Recent Developments

Table 76. Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Basic Information

Table 77. Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Product Overview

Table 78. Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 79. Janssen Pharmaceutical Companies Business Overview

Table 80. Janssen Pharmaceutical Companies Recent Developments

Table 81. Altimmune COVID-19 Inactivated Vaccine Basic Information

Table 82. Altimmune COVID-19 Inactivated Vaccine Product Overview

Table 83. Altimmune COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 84. Altimmune Business Overview

Table 85. Altimmune Recent Developments

Table 86. Vaxart COVID-19 Inactivated Vaccine Basic Information

Table 87. Vaxart COVID-19 Inactivated Vaccine Product Overview

Table 88. Vaxart COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 89. Vaxart Business Overview

Table 90. Vaxart Recent Developments

Table 91. CanSino Biologics COVID-19 Inactivated Vaccine Basic Information

Table 92. CanSino Biologics COVID-19 Inactivated Vaccine Product Overview

Table 93. CanSino Biologics COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 94. CanSino Biologics Business Overview

Table 95. CanSino Biologics Recent Developments

Table 96. ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Basic Information

Table 97. ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Product Overview

Table 98. ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 99. ExpreS2ion Biotechnologies ApS Business Overview

Table 100. ExpreS2ion Biotechnologies ApS Recent Developments

Table 101. Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Basic Information

Table 102. Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Product Overview

Table 103. Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 104. Clover Biopharmaceuticals Business Overview

Table 105. Clover Biopharmaceuticals Recent Developments

Table 106. GSK COVID-19 Inactivated Vaccine Basic Information

Table 107. GSK COVID-19 Inactivated Vaccine Product Overview

Table 108. GSK COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 109. GSK Business Overview

Table 110. GSK Recent Developments

Table 111. Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Basic Information

Table 112. Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Product Overview

Table 113. Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M

USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 114. Vaxil Bio Ltd. Business Overview

Table 115. Vaxil Bio Ltd. Recent Developments

Table 116. Generex COVID-19 Inactivated Vaccine Basic Information

Table 117. Generex COVID-19 Inactivated Vaccine Product Overview

Table 118. Generex COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 119. Generex Business Overview

Table 120. Generex Recent Developments

Table 121. Novavax, Inc. COVID-19 Inactivated Vaccine Basic Information

Table 122. Novavax, Inc. COVID-19 Inactivated Vaccine Product Overview

Table 123. Novavax, Inc. COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 124. Novavax, Inc. Business Overview

Table 125. Novavax, Inc. Recent Developments

Table 126. Sanofi Pasteur COVID-19 Inactivated Vaccine Basic Information

Table 127. Sanofi Pasteur COVID-19 Inactivated Vaccine Product Overview

Table 128. Sanofi Pasteur COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 129. Sanofi Pasteur Business Overview

Table 130. Sanofi Pasteur Recent Developments

Table 131. Baylor COVID-19 Inactivated Vaccine Basic Information

Table 132. Baylor COVID-19 Inactivated Vaccine Product Overview

Table 133. Baylor COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 134. Baylor Business Overview

Table 135. Baylor Recent Developments

Table 136. iBio, Inc. COVID-19 Inactivated Vaccine Basic Information

Table 137. iBio, Inc. COVID-19 Inactivated Vaccine Product Overview

Table 138. iBio, Inc. COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 139. iBio, Inc. Business Overview

Table 140. iBio, Inc. Recent Developments

Table 141. Moderna, Inc. COVID-19 Inactivated Vaccine Basic Information

Table 142. Moderna, Inc. COVID-19 Inactivated Vaccine Product Overview

Table 143. Moderna, Inc. COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 144. Moderna, Inc. Business Overview

Table 145. Moderna, Inc. Recent Developments

- Table 146. Curevac COVID-19 Inactivated Vaccine Basic Information
- Table 147. Curevac COVID-19 Inactivated Vaccine Product Overview
- Table 148. Curevac COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 149. Curevac Business Overview
- Table 150. Curevac Recent Developments
- Table 151. ImmunoPrecise COVID-19 Inactivated Vaccine Basic Information
- Table 152. ImmunoPrecise COVID-19 Inactivated Vaccine Product Overview
- Table 153. ImmunoPrecise COVID-19 Inactivated Vaccine Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 154. ImmunoPrecise Business Overview
- Table 155. ImmunoPrecise Recent Developments
- Table 156. Global COVID-19 Inactivated Vaccine Sales Forecast by Region (2025-2030) & (K Units)
- Table 157. Global COVID-19 Inactivated Vaccine Market Size Forecast by Region (2025-2030) & (M USD)
- Table 158. North America COVID-19 Inactivated Vaccine Sales Forecast by Country (2025-2030) & (K Units)
- Table 159. North America COVID-19 Inactivated Vaccine Market Size Forecast by Country (2025-2030) & (M USD)
- Table 160. Europe COVID-19 Inactivated Vaccine Sales Forecast by Country (2025-2030) & (K Units)
- Table 161. Europe COVID-19 Inactivated Vaccine Market Size Forecast by Country (2025-2030) & (M USD)
- Table 162. Asia Pacific COVID-19 Inactivated Vaccine Sales Forecast by Region (2025-2030) & (K Units)
- Table 163. Asia Pacific COVID-19 Inactivated Vaccine Market Size Forecast by Region (2025-2030) & (M USD)
- Table 164. South America COVID-19 Inactivated Vaccine Sales Forecast by Country (2025-2030) & (K Units)
- Table 165. South America COVID-19 Inactivated Vaccine Market Size Forecast by Country (2025-2030) & (M USD)
- Table 166. Middle East and Africa COVID-19 Inactivated Vaccine Consumption Forecast by Country (2025-2030) & (Units)
- Table 167. Middle East and Africa COVID-19 Inactivated Vaccine Market Size Forecast by Country (2025-2030) & (M USD)
- Table 168. Global COVID-19 Inactivated Vaccine Sales Forecast by Type (2025-2030) & (K Units)
- Table 169. Global COVID-19 Inactivated Vaccine Market Size Forecast by Type

(2025-2030) & (M USD)

Table 170. Global COVID-19 Inactivated Vaccine Price Forecast by Type (2025-2030) & (USD/Unit)

Table 171. Global COVID-19 Inactivated Vaccine Sales (K Units) Forecast by Application (2025-2030)

Table 172. Global COVID-19 Inactivated Vaccine Market Size Forecast by Application (2025-2030) & (M USD)

List Of Figures

LIST OF FIGURES

- Figure 1. Product Picture of COVID-19 Inactivated Vaccine
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global COVID-19 Inactivated Vaccine Market Size (M USD), 2019-2030
- Figure 5. Global COVID-19 Inactivated Vaccine Market Size (M USD) (2019-2030)
- Figure 6. Global COVID-19 Inactivated Vaccine Sales (K Units) & (2019-2030)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. COVID-19 Inactivated Vaccine Market Size by Country (M USD)
- Figure 11. COVID-19 Inactivated Vaccine Sales Share by Manufacturers in 2023
- Figure 12. Global COVID-19 Inactivated Vaccine Revenue Share by Manufacturers in 2023
- Figure 13. COVID-19 Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
- Figure 14. Global Market COVID-19 Inactivated Vaccine Average Price (USD/Unit) of Key Manufacturers in 2023
- Figure 15. The Global 5 and 10 Largest Players: Market Share by COVID-19 Inactivated Vaccine Revenue in 2023
- Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 17. Global COVID-19 Inactivated Vaccine Market Share by Type
- Figure 18. Sales Market Share of COVID-19 Inactivated Vaccine by Type (2019-2024)
- Figure 19. Sales Market Share of COVID-19 Inactivated Vaccine by Type in 2023
- Figure 20. Market Size Share of COVID-19 Inactivated Vaccine by Type (2019-2024)
- Figure 21. Market Size Market Share of COVID-19 Inactivated Vaccine by Type in 2023
- Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 23. Global COVID-19 Inactivated Vaccine Market Share by Application
- Figure 24. Global COVID-19 Inactivated Vaccine Sales Market Share by Application (2019-2024)
- Figure 25. Global COVID-19 Inactivated Vaccine Sales Market Share by Application in 2023
- Figure 26. Global COVID-19 Inactivated Vaccine Market Share by Application (2019-2024)
- Figure 27. Global COVID-19 Inactivated Vaccine Market Share by Application in 2023
- Figure 28. Global COVID-19 Inactivated Vaccine Sales Growth Rate by Application

(2019-2024)

Figure 29. Global COVID-19 Inactivated Vaccine Sales Market Share by Region

(2019-2024)

Figure 30. North America COVID-19 Inactivated Vaccine Sales and Growth Rate

(2019-2024) & (K Units)

Figure 31. North America COVID-19 Inactivated Vaccine Sales Market Share by

Country in 2023

Figure 32. U.S. COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) &

(K Units)

Figure 33. Canada COVID-19 Inactivated Vaccine Sales (K Units) and Growth Rate

(2019-2024)

Figure 34. Mexico COVID-19 Inactivated Vaccine Sales (Units) and Growth Rate

(2019-2024)

Figure 35. Europe COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024)

& (K Units)

Figure 36. Europe COVID-19 Inactivated Vaccine Sales Market Share by Country in

2023

Figure 37. Germany COVID-19 Inactivated Vaccine Sales and Growth Rate

(2019-2024) & (K Units)

Figure 38. France COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024)

& (K Units)

Figure 39. U.K. COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) &

(K Units)

Figure 40. Italy COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) &

(K Units)

Figure 41. Russia COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) &

(K Units)

Figure 42. Asia Pacific COVID-19 Inactivated Vaccine Sales and Growth Rate (K Units)

Figure 43. Asia Pacific COVID-19 Inactivated Vaccine Sales Market Share by Region in

2023

Figure 44. China COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) &

(K Units)

Figure 45. Japan COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) &

(K Units)

Figure 46. South Korea COVID-19 Inactivated Vaccine Sales and Growth Rate

(2019-2024) & (K Units)

Figure 47. India COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) &

(K Units)

Figure 48. Southeast Asia COVID-19 Inactivated Vaccine Sales and Growth Rate

(2019-2024) & (K Units)

Figure 49. South America COVID-19 Inactivated Vaccine Sales and Growth Rate (K Units)

Figure 50. South America COVID-19 Inactivated Vaccine Sales Market Share by Country in 2023

Figure 51. Brazil COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa COVID-19 Inactivated Vaccine Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa COVID-19 Inactivated Vaccine Sales Market Share by Region in 2023

Figure 56. Saudi Arabia COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa COVID-19 Inactivated Vaccine Sales and Growth Rate (2019-2024) & (K Units)

Figure 61. Global COVID-19 Inactivated Vaccine Sales Forecast by Volume (2019-2030) & (K Units)

Figure 62. Global COVID-19 Inactivated Vaccine Market Size Forecast by Value (2019-2030) & (M USD)

Figure 63. Global COVID-19 Inactivated Vaccine Sales Market Share Forecast by Type (2025-2030)

Figure 64. Global COVID-19 Inactivated Vaccine Market Share Forecast by Type (2025-2030)

Figure 65. Global COVID-19 Inactivated Vaccine Sales Forecast by Application (2025-2030)

Figure 66. Global COVID-19 Inactivated Vaccine Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global COVID-19 Inactivated Vaccine Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/G7AEB83095E7EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7AEB83095E7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970